Secondary Endpoint

Secondary Endpoint

  1. lut 28, 2025

What Does the 'Secondary Endpoint’ Mean?

A secondary endpoint is an additional outcome measure in a clinical trial that is not the primary focus of the study. These endpoints are used to evaluate other effects of the intervention or treatment being tested, providing supplementary information to support or complement the primary endpoint results.

Secondary endpoints are typically specified in the study protocol and analyzed after the primary endpoint. While they may offer valuable insights, secondary endpoints generally carry less statistical power and are considered supportive rather than definitive evidence of a treatment’s efficacy or safety.

Why Is the 'Secondary Endpoint’ Important in Clinical Research?

Secondary endpoints play a crucial role in providing a more comprehensive understanding of a treatment’s effects beyond the primary outcome. They allow researchers to explore additional aspects of efficacy, safety, or quality of life that may be relevant to patients, healthcare providers, or regulatory agencies.

The inclusion of secondary endpoints enhances the overall value of a clinical trial by maximizing the information gathered from study participants. This broader assessment can help identify unexpected benefits or risks, guide future research directions, and inform clinical decision-making, even if the primary endpoint does not meet its objectives.

Good Practices and Procedures

  1. Prioritize secondary endpoints based on clinical relevance and align them with the study’s overall objectives to maintain focus and avoid data overload.
  2. Implement statistical adjustments for multiple comparisons, such as the Bonferroni correction, to control the family-wise error rate when analyzing multiple secondary endpoints.
  3. Prespecify a clear hierarchy of secondary endpoints in the study protocol to guide interpretation and reporting of results, especially when regulatory claims are intended.
  4. Consider using composite secondary endpoints to capture a broader range of clinically meaningful outcomes while reducing the number of statistical tests performed.
  5. Conduct sensitivity analyses on secondary endpoints to assess the robustness of findings and explore potential sources of bias or confounding factors.

Related Terms

Read more

How clinical trials can become a strategic asset for biotech startups

Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…

Advancing PET Innovation at SNMMI 2025

Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…

Insights from Turku PET Symposium 2025

Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…